NCT02184741 - A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 3, 2014

Primary Completion Date

May 31, 2020

Study Completion Date

September 30, 2020

Conditions

Recurrent Miscarriage

Interventions

DRUG

GB-0998

Subjects received GB-0998 at 400 mg/kg body weight once daily for 5 days until 6 weeks and 6 days of gestation after confirmation of the gestational sac by ultrasonography.

DRUG

Placebo

Subjects received the same dose of saline as GB-0998 for 5 days after confirmation of the gestational sac by ultrasonography, up to 6 weeks and 6 days of gestation.

Trial Locations (1)

Unknown

Japan Blood Products Organization, Tokyo